Cingulate (CING)

Executive Summary

Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company leveraging its proprietary Precision Timed Release™ (PTR™) platform to develop novel therapeutics for central nervous system disorders, primarily Attention Deficit/Hyperactivity Disorder (ADHD). The platform enables multi-release formulations from a single tablet, designed to provide rapid onset followed by controlled duration of action. Cingulate's lead candidate, CTx-1301 (dexmethylphenidate), is a non-stimulant treatment for ADHD that has completed multiple Phase 3 trials and currently has an active Phase 3 study (NCT05924594) with an estimated completion date in March 2026. The company is also developing CTx-1302 (dextroamphetamine) and a pipeline of earlier-stage candidates for ADHD and anxiety disorders. With a market cap of approximately $65 million (estimated), Cingulate operates in a competitive biotech landscape, where near-term value hinges on successful clinical data and regulatory milestones.

Upcoming Catalysts (preview)

• Q2 2026Top-line Phase 3 data for CTx-1301 (NCT05924594)60% success
• H2 2026Potential NDA submission for CTx-130140% success
• 2026Partnership or licensing agreement for PTR platform30% success